Who to call at Kyverna Therapeutics, Inc., and when
Fundz watches for the moments Kyverna Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Kyverna Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kyverna Therapeutics, Inc., from your own LinkedIn network
Kyverna Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
kyvernatx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Kyverna Therapeutics announced positive one-year data from its registrational trial KYSA-8 for miv-cel in stiff person syndrome patients, along with favorable long-term follow-up data from the Phase 2 KYSA-6 trial in generalized myasthenia gravis patients, marking significant clinical development milestones.
Key Takeaways
One-year data from registrational trial KYSA-8 demonstrates positive efficacy and safety for miv-cel in stiff person syndrome
Long-term follow-up data from Phase 2 trial KYSA-6 shows favorable results in generalized myasthenia gravis patients
2 more takeaways
Filing Overview
What This Means
Kyverna Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.